研究目的
To develop a novel drug controlled release system based on mesoporous silica nanoparticles (MSNs) with gold nanoparticles (AuNPs) acting as pore caps and short single-stranded DNA (ssDNA) oligomers as the linker, aiming to improve drug efficacy and reduce toxicity and side effects.
研究成果
The developed MCM-41–ssDNA–AuNP system successfully demonstrated controlled drug release under NIR laser stimulation, with release rates adjustable by laser power and pH conditions. This system holds promise for targeted cancer therapy, offering a method to minimize side effects and improve treatment efficacy.
研究不足
The study's limitations include the need for further in vivo testing to validate the system's efficacy and safety in biological systems. Additionally, the photothermal effect's impact on surrounding tissues requires further investigation.
1：Experimental Design and Method Selection:
The study involved the synthesis of a drug nanocarrier using MSNs capped with AuNPs via ssDNA linkers. The system was designed to release drugs upon NIR laser stimulation.
2：Sample Selection and Data Sources:
MCM-41 type MSNs and 3 nm AuNPs were used. Doxorubicin was chosen as the model drug.
3：List of Experimental Equipment and Materials:
Equipment included FTIR, XRD, TGA, zeta potential analyzer, TEM, UV-vis spectrophotometer, and fluorescence spectrophotometer. Materials included MCM-41, AuNPs, ssDNA, APTES, EDC, NHS, Dox, and PBS.
4：Experimental Procedures and Operational Workflow:
The process involved modifying MCM-41 with amine groups, immobilizing ssDNA, loading Dox, capping with AuNPs, and studying drug release under NIR laser irradiation at different pH levels.
5：Data Analysis Methods:
Drug release was monitored using fluorescence spectroscopy, and the system's response to NIR laser was analyzed.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
